CJ BIO today announced the completion of an additional increment of threonine capacity at the company’s U.S. Fort Dodge, Iowa plant. CJ announced in August of 2020 the completion of the FDA evaluation for Thr Pro, an 80% active granular source of L-threonine, with residual biomass.
“Initial plant capacity was twenty thousand metric tons which required an investment of $50 million. Through process enhancements, additional permitting, and efficiency improvements, our team is now producing at thirty thousand metric tons per year,” commented Joe Lucas, Vice President and GM – Animal Nutrition and Health at CJ America. “Based on the commercial acceptance of Thr Pro, we are also pleased to announce approval for an additional twenty thousand metric tons of capacity, which we will bring on stream in the second quarter of 2022. We will invest another $20 million over the next eighteen months to achieve a total threonine capacity of 50 thousand metric tons. The investment will also allow CJ to begin valine production at the Fort Dodge plant,” added Lucas.
“We are committed to continue the expansion of our North America operations in the state of Iowa to optimize efficient operations and better serve customers,” added Harry Jang, Head of CJ BIO for North and South America.
CJ BIO is a division of CJ CheilJedang, a core subsidiary in charge of the food and bioengineering business Unit of the CJ Group. CJ Group has developed its business portfolio into four core sectors – Food & Food Service, Bio & Pharma, Entertainment & Media, and Retail & Logistics.
